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Tuberous sclerosis complex (TSC), an autosomal dominant disease caused by mutations in either TSC1 or TSC2,
is characterized by the development of hamartomas in a variety of organs. Concordant with the tumor-suppressor
model, loss of heterozygosity (LOH) is known to occur in these hamartomas at loci of both TSC1 and TSC2. LOH
has been documented in renal angiomyolipomas (AMLs), but loss of the wild-type allele in cortical tubers appears
to be very uncommon. Analysis of second, somatic events in tumors for which the status of both TSC1 and TSC2
is known is essential for exploration of the pathogenesis of TSC-lesion development. We analyzed 24 hamartomas
from 10 patients for second-hit mutations, by several methods, including LOH, scanning of all exons of both TSC1
and TSC2, promoter methylation of TSC2, and clonality analysis. Our results document loss of the wild-type allele
in six of seven AMLs, without evidence of the inactivation of the second allele in many of the other lesions, including
tumors that appear to be clonally derived. Laser-capture microdissection further demonstrated loss of the second
allele in all three cellular components of an AML. This study thus provides evidence that, in both TSC1 and TSC2,
somatic mutations resulting in the loss of wild-type alleles may not be necessary in some tumor types—and that
other mechanisms may contribute to tumorigenesis in this setting.
Introduction
Tuberous sclerosis complex (TSC) is an autosomal dom-
inant disorder characterized by seizures, mental retarda-
tion, and multiple hamartomas in many organs. Major
TSC lesions include cortical tubers, subependymal nod-
ules (SENs) and subependymal giant-cell astrocytomas
(SEGAs) in the brain, multiple retinal nodular hamarto-
mas, hypomelanotic macules, facial angiofibromas, sha-
green patch and periungual fibromas of the skin, cardiac
rhabdomyomas, renal angiomyolipomas (AMLs), and
pulmonary lymphangioleiomyomatosis (LAM). TSC
displays genetic heterogeneity involving two different
causative genes on chromosomes 9q34.3—TSC1 (MIM
605284)—and 16p13.3—TSC2 (MIM 191092) (The
European Chromosome 16 Tuberous Sclerosis Consor-
tium 1993; van Slegtenhorst et al. 1997). The TSC1 gene
has 21 coding exons and 2 leader exons; the TSC2 gene
has 41 coding exons with multiple-transcript isoforms,
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because of the alternative splicing of exons 25 and 31
(Xu et al. 1995; Olsson et al. 1996), and a leader exon
1a–encoding core promoter sequence (Maheshwar et al.
1996; Kobayashi et al. 1997). Large-scale cohort studies
of comprehensive germline-mutation analysis have de-
tected, among sporadic cases, a higher frequency of
TSC2 mutations compared to TSC1 mutations (Au et
al. 1998; Jones et al. 1999; Niida et al. 1999; Dabora
et al. 2001). The TSC1 protein, hamartin, and the TSC2
protein, tuberin, interact with each other in vivo, indi-
cating that these two proteins participate in at least some
common biochemical pathways (Plank et al. 1998; van
Slegtenhorst et al. 1998; Nellist et al. 1999; Murthy et
al. 2000).
Loss of heterozygosity (LOH) of both TSC1 and
TSC2 has been documented in TSC hamartomas, sup-
porting the classification of the TSC genes as tumor-
suppressor genes (Carbonara et al. 1994; Green et al.
1994; Henske et al. 1996; Sepp et al. 1996; van Sleg-
tenhorst et al. 1997). However, LOH frequencies vary
significantly among tumor types. Renal AMLs reveal a
high frequency of LOH, whereas CNS lesions show a
low frequency of LOH (Henske et al. 1996). Similarly,
renal cellular carcinomas in the Eker rat, a naturally
occurring model in which the homologous Tsc2 gene is
mutated, show a higher frequency of LOH, compared
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to other tumors in these animals (Kubo et al. 1994,
1995; Yeung et al. 1995). Mice with Tsc2/ also display
a variable frequency of LOH in their tumors (Onda et
al. 1999).
Although LOH studies in a variety of TSC hamar-
tomas have been performed by several investigators, a
systematic study of somatic mutations in TSC lesions
has not been reported. A recent study performed on
renal AMLs, cortical tubers, and facial angiofibromas
from patients with TSC who are known to have germ-
line mutations in TSC2 showed, in a majority of the
AMLs, LOH and, in two of the three angiofibromas,
an intragenic deletion spanning 22–25 kb, thus docu-
menting the complete inactivation of TSC2 (Au et al.
1999). This study, however, failed to detect the somatic
mutations in cortical tubers. Failure to demonstrate the
somatic events in TSC hamartomas has been attributed
either to subtle variations in the TSC genes or to a
mixture of normal and abnormal cells in the lesions (Au
et al. 1999; Cheadle et al. 2000). We therefore under-
took a detailed analysis of the somatic mutations in 24
hamartomas obtained from 10 different patients with
TSC in whom germline TSC1/TSC2 mutations have
been screened. Our results suggest that AMLs frequently
exhibit the loss of both alleles of the TSC genes, without
evidence of the inactivation of the second allele in many
of the other lesions. Tumors that appear to be clonally
derived still do not harbor the second, somatic event,
raising the possibilities that second-hit mutations are
not necessary and that other mechanisms may contrib-
ute to some TSC lesions.
Subject and Methods
Sample Collection
Twenty-four hamartomas obtained from 10 different
patients with TSC were included in this study. Tissue
samples were collected from various sources, including
the TSC Clinic at Massachusetts General Hospital, re-
ferrals from the Tuberous Sclerosis Alliance, and private
physicians. All cases were clinically diagnosed according
to established criteria (Roach et al. 1998). This study
was approved by the Institutional Review Board ofMas-
sachusetts General Hospital. All living persons donating
tissue to this work provided informed consent. Patients
1–7 in this study have been described elsewhere (Beau-
champ et al. 1998; Niida et al. 1999). Patient 8 had
severe pulmonary TSC, and three LAM samples were
taken at the time of lung transplantation; LAM 1 was
somewhat fibrotic, and LAMs 2 and 3 had abundant
amounts of smooth-muscle cells. Patient 9 had multiple-
organ involvement with fatal renal failure caused by
massive growth of bilateral multiple renal AMLs; AMLs
and other tumor samples were obtained through an au-
topsy. Patient 10 had all of the characteristics of the TSC
phenotype, except for mental retardation.
For the majority of samples, DNA was extracted from
frozen tissues by standard proteinase-K digestion fol-
lowed by phenol/chloroform extraction and ethanol
precipitation. For four samples (an AML of patient 2,
a SEGA of patient 4, and cardiac rhabdomyomas of
patients 5 and 6), DNA was extracted from paraffin-
embedded tissues. In brief, after the scraped tissues were
deparaffinized by xylene, samples were washed several
times with ethanol and were digested in buffer (1# Tris-
EDTA [pH 8.0], 0.5% Tween 20, and 1 mg of protein-
ase-K/ml) at 50C for 3–5 d, followed by phenol/chloro-
form extraction and ethanol precipitation.
LOH Analysis
Chromosomalmarkers D9S2126,D9S1830,D9S1199,
and D9S1198, flanking the TSC1 locus; chromosomal
markers D16S663, D16S665, D16S525, and Kg8, flank-
ing the TSC2 locus; and an intragenic EcoRV polymor-
phism in exon 40 of the TSC2 gene were tested for LOH
in hamartomas. All markers other than the TSC2 EcoRV
polymorphism were analyzed by PCR amplification using
[32P]a-dGTP, followed by separation on a sequencing gel
and then autoradiography. Primer sequences for these
markers are available at The Genome Database. For the
TSC2 EcoRV polymorphism, PCR was performed with
TSC2 exon 40 primers, and PCR products were digested
with EcoRV and electrophoresed on 1% agarose gels (Au
et al. 1999). In addition, whenever possible, identified
germline mutations were used as additional LOH mark-
ers. When the germline mutation was a small deletion,
PCR products were run on 8% sequencing gels. When
the germline mutation was a single-base-pair substitution,
LOH was assessed at these sites by SSCP and direct se-
quencing. In every analysis, only when the intensity, com-
pared to that in the blood control, of one allele was de-
creased 150% was LOH scored as positive (Louis et al.
1992).
Screening for Intragenic Somatic Mutations
To detect small intragenic second-hit mutations, tu-
mor DNA was screened, by SSCP, for all coding exons
of both TSC1 and TSC2 genes, as described elsewhere
for germline-mutation screening (Beauchamp et al.
1998; Niida et al. 1999). Any detected SSCP shift was
directly sequenced, to determine whether it represented
a mutation or a polymorphism. Also, tubers 1, 4, and
5 of patient 9 were tested by denaturing high-perform-
ance liquid chromatography (DHPLC) for possible
TSC2mutations, by methods described elsewhere (Choy
et al. 1999; Dabora et al. 2001).
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To screen for relatively large gene rearrangements, we
performed long-range PCR and Southern blot analyses.
Long-range PCR was performed for both TSC1 and
TSC2, with primers and conditions reported by Jones et
al. (1999). However, three primers—TSC2 7-15F (TGA-
GCCTCAGGAGTCCCCCATGTAAG), 7-15R (TGAG-
ACCACCGCACCCTCAGCAAATC), and 26-41F (AC-
GCCCTGTTGGGGTCTTTCCGAG)—were resynthe-
sized, since the published primers were not optimal for
our PCR analysis. For tumors in which a sufficient quan-
tity of DNAwas available, Southern blot analysis ofTSC2
was performed. A total of 10 mg of DNA in samples
digested with either EcoRI or HindIII was separated on
a 0.7% agarose gel, transferred to positively charged ny-
lon membrane (Hybond N; Amersham), and probed,
by standard methods, with TSC2 full-length cDNA la-
beled with [32P]a-dGTP.
Methylation Analysis
To check for hypermethylation of the TSC2 promoter,
a PCR-based technique to detect hypermethylation of the
HpaII or SmaI site within exon 1a was employed. After
complete digestion byHpaII or SmaI, DNA samples were
amplified with TSC2 exon 1a–specific primers (forward,
GGCGGCACAGAACTACAACT; and reverse, CACCC-
GCCATGACTTAAAAC) under standard PCR condi-
tions, with 5% dimethyl sulfoxide (DMSO). The same
samples were also amplified for exon 1, which served as
a control for a failure of the PCR reaction of exon 1a.
Primers for exon 1 amplification were the same primers
used in SSCP analysis of exon 1. DNA samples treated
with restriction-enzyme buffer but without enzyme were
also used as positive controls for exon 1a amplification.
Amplification products were analyzed by 1% agarose-gel
electrophoresis followed by ethidium bromide staining.
Allelic Expression, by Reverse-Transcription PCR
(RT-PCR), in Cortical Tubers
RT-PCR was performed to determine the mRNA-
expression level of the wild-type allele in cortical tubers
from patient 9. Frozen tissue samples were powdered
on dry ice, and RNA was immediately extracted with
TRIzol (Gibco). cDNA was synthesized with the
SuperScript Preamplification System for First-Strand
cDNA Synthesis (Gibco). RT-PCR was performed, for
20 cycles, with 5%DMSO, [32P]a-dCTP, andTSC2 exon
33 primers (forward, ATCCCCATCGAGCGAGTCGT-
CTCCTC; and reverse, ACCAGGCAGCACTTTCCCC-
GTCCA). To eliminate the possibility of DNA contam-
ination, RNA samples extracted from normal gray
matter of the patient were subjected to PCR without RT.
Samples were run on a sequence gel at 80 W for 3 h
and were developed by autoradiography.
Laser-Capture Microdissection (LCMD) Analysis
LCMD was performed with the Arcturus PixCell 2
system. Cells were dissected from 4-mm-thick, paraffin-
embedded sections and were stained with a modified
hematoxylin-and-eosin stain. DNA was extracted from
microdissected cells, after digestion with proteinase-K
for 3–5 d. One to two microliters of the microdissected
sample of DNA was used as a template for PCR.
Clonality Analysis
To check the clonality of the tumor samples, a PCR-
based assay with the human androgen-receptor gene, or
HUMARA,was performed as described elsewhere (Allen
et al. 1992; Green et al. 1996). In brief, 1 mg of genomic
DNA was digested, for 48 h, with 10 U of HpaII in a
20-ml reaction volume at 37C, and 2 ml of digestedDNA
was subjected to PCR in the presence of [32P]a-dCTP.
After PCR, an equal amount of loading buffer (50%
glycerol in 0.5# Tris-EDTA with bromophenol blue)
was added to the reaction; 1 ml of each sample was
loaded onto a nondenaturing, 8% polyacrylamide gel
containing 8% glycerol and electrophoresed at 10 W for
17 h at room temperature, and autoradiography was
performed. The autoradiographs were scanned with the
Fluor-S-Multiimager Analyzer (Bio-Rad), to quantitate
the two X-linked alleles generated by the HUMARA
clonality assay. The clonality ratio (CR) was determined
through the published procedure with the criteria that
a polyclonal sample will have a CR of ∼1.0 and that a
sample containing an appreciable percentage (150%) of
clonal cells will have a CR of 13.0 (Zhu et al. 1995).
Results
Germline Mutations
A panel of 10 patients with TSC who have a variety
of hamartomas were included in this study. Of particular
interest is patient 9, an autopsy case of TSC from whom
two AMLs, five tubers, two SEGAs, and an ungual fi-
broma (UF) were available. The germline mutations in
patients 1–7 have been reported elsewhere (Beauchamp
et al. 1998; Niida et al. 1999), whereas the germline mu-
tations in patients 8 and 9—E19 2109 GrA (W703X)
and E33 4207delG (D1400fsr1410X), respectively—are
novel TSC2 mutations. We were unable to identify the
germline mutation in patient 10 (table 1).
LOH Analysis of Hamartomas
The hamartomas were tested for allelic loss, by LOH
analysis with markers at and surrounding the TSC1 and
TSC2 genes. All samples were informative for at least
one marker, at both loci. LOH at the TSC1 gene was
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Figure 1 TSC lesions with LOH. Decreased intensity of the
lower allele for D9S1198 is seen in AML (A) of patient 2 (P2), com-
pared to the blood control (B). Similarly, for D16S525, loss of the
upper allele is seen in AML (A) of patient 7 (P7) and in all three AMLs
(A1–A3) of patient 10 (P10). Patient 4 (P4) is informative for the
EcoRV polymorphism in exon 40 of TSC2, with the PCR product
from blood digested with EcoRV (B/EV) showing three bands, at 583
bp, 389 bp, and 194 bp; and the 583-bp band is lost in the SEGA (S/
EV) sample of this patient; undigested products from blood (B) and
the SEGA (S) are shown as controls. Blackened arrows indicate the
two alleles of each marker, and unblackened arrowheads indicate the
lost allele.
Figure 2 LOHanalysis of various lesions from patient 9.Normal
spleen tissue (SP), two AMLs (A1 and A2), five cortical tubers (T1–T5),
two SEGAs (S1 and S2), a UF (UF), and a gastric polyp (GP) were
examined for LOH at the TSC1 and TSC2 loci. Kg8 as well as the
germline mutation in exon 33 of TSC2 in this patient reveal LOH only
in AML 1 (A1). Decreased intensity—of the wild-type allele (WT)
compared to the 1-bp–deleted mutant allele (M), which represents the
germline mutation (GLM)—is noticeable. A normal, unrelated control
(NC) in which only the wild-type allele is amplified is also included
in the analysis.
detected in one AML from patient 2 (fig. 1), and no
evidence of LOH was seen in a UF and a SEGA obtained
from patients 1 and 3, respectively, who harbor germline
mutations in the TSC1 gene. LOH for the TSC2 gene
was observed in one SEGA (patient 4; fig. 1) and in six
AMLs obtained from three unrelated patients (patients
7, 9, and 10; figs. 1 and 2). All three AML samples
obtained from patient 10 revealed the same pattern of
LOH (table 1). Among the two AMLs obtained from
patient 9, only AML 1 showed LOH. Other lesions,
including the 5 tuber samples obtained from this patient,
showed no evidence of LOH at the TSC2 locus (fig. 2).
In those tumors where LOH was detected, it was ap-
parent that this involved deletion of the complete TSC1
or TSC2 wild-type allele, leaving the nonfunctional mu-
tant germline allele.
Analysis of Other Possible Somatic Mutations in the
TSC1 and TSC2 Genes
The absence of LOH in many of the tumor samples
raised the possibility that more-subtle mutations caused
loss of function of the second allele in these tumors. We
therefore analyzed the individual exons of the TSC1 and
TSC2 genes, by SSCP screening, as described elsewhere
(Beauchamp et al. 1998; Niida et al. 1999). A UF from
patient 1, who has a TSC1 germline mutation, was
screened only for TSC1, owing to an insufficient amount
of DNA. Similarly, the SEGA from patient 4 was not
screened by SSCP, owing to insufficient DNA; however,
LOH at the TSC2 locus was detected in this sample. All
other tumors were screened for the entire TSC1 and
TSC2 coding sequences. This analysis, in addition to
confirming the respective germline mutations in all the
tumor samples, identified, in exon 33 of TSC2, a com-
plex 14-bp deletion causing a frameshift and pre-
mature termination (4358–4359del and 4361–4372del;
P1453fsr1518X) in AML 1 of patient 9. This 14-bp
deletion was near the germline mutation in exon 33 of
this patient, and, by sequencing exon 33 of TSC2, we
further confirmed that this somatic event was present in
the wild-type allele. AML 1 also displayed LOH at the
TSC2 locus. Thus, two distinct somatic events in this
AML raised the possibility that either a second, cell-
specific event or two independent somatic events oc-
curred in this tumor. To clarify this further, we performed
LCMD (see following subsection, “LCMD”).
In all other tumors analyzed, no mutations other than
the germline mutation were detected by SSCP screening.
Since enough DNA was available for tubers 1, 4, and 5
obtained from patient 9, these samples were subjected
to DHPLC analysis, in a search for subtle mutations that
might have been missed by initial SSCP analysis. DHPLC
also failed to detect a somatic event in these tubers, al-
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Table 2
Intragenic-Mutation and Promoter-Methylation Analyses of TSC
Lesions
PATIENT
TUMOR
TYPEa
ANALYSIS OFb
TSC1/TSC2 TSC2
SSCP
Long-Range
PCR
Southern
Blot
Promoter
Methylation
1 UF NSo/… …/… … …
2 AML NSo/NS …/… … U
3 SEGA NSo/NS N/N … U
4 SEGA …/… …/… … …
5 Rhabdo NS/NSo …/… … U
6 Rhabdo NS/NSo …/… … U
7 AML NS/NSo …/… … U
8 LAM 1 NS/NSo N/N N U
LAM 2 NS/NSo N/N N U
LAM 3 NS/NSo N/N N U
9 AML 1 NS/E33c N/N N U
AML 2 NS/NSo N/N N U
Tuber 1 NS/NSo N/N N U
Tuber 2 NS/NSo N/N N U
Tuber 3 NS/NSo N/N N U
Tuber 4 NS/NSo N/N … U
Tuber 5 NS/NSo N/N … U
SEGA 1 NS/NSo N/N N U
SEGA 2 NS/NSo N/N N U
UF NS/NSo N/N N U
GP NS/NSo N/N N U
10 AML 1 NS/NS N/N N U
AML 2 NS/NS N/N N U
AML 3 NS/NS N/N N U
a For abbreviations, see table 1.
b NS p no shift; NSo p no shift other than germline mutation; N
p normal; Up unmethylated; an ellipsis (…) denotes that the sample
was not tested, owing to inadequate sample quantity.
c Complex 14-bp deletion of wild-type allele (see text).
Figure 3 RT-PCR of cortical tubers derived from patient 9. Three
cortical tubers (T1, T4, and T5), as well as normal gray matter (NG)
and normal white matter (NW) from the same patient, were tested for
allelic expression of the wild-type and 1-bp–deleted alleles in exon 33.
Fibroblast cDNA from a normal, unrelated person was amplified, as a
control. In all three tubers, the wild-type–allele (WT):mutant-allele (M)
intensity ratio is not altered compared to that in normal gray or white
matter. RNA from the normal-gray-matter sample without RTwas used
as a negative control, to exclude DNA contamination in the RNA
preparations.
though the germline mutation was confirmed. Our at-
tempts to detect other intragenic deletions, by Southern
blot and long-range PCR analyses of the tumors with
sufficient DNA, also failed to detect any variations (table
2). Hypermethylation of the wild-type alleles, leading to
epigenetic gene silencing, was considered, and no evi-
dence of methylation of the TSC2 promoter region was
noted (data not shown). Furthermore, in order to de-
termine the mRNA-expression level of the wild-type al-
lele, RT-PCR analysis was performed for the region
spanning the germline mutation (1-bp deletion in TSC2
exon 33) in tubers 1, 4, and 5 as well as in normal gray
and white matter obtained from this patient. In these
three tubers, the wild-type–allele:mutant-allele intensity
ratio was similar to the intensity ratio obtained from the
normal brain samples (fig. 3).
LCMD
To examine whether specific cell types in AML 1 could
be associated with LOH and the 14-bp deletion, we per-
formed LCMD on this tumor and isolated the three com-
ponents that comprise AMLs: blood vessels, smooth
muscle, and fat. LCMD was performed on sequential
slices of the paraffin-embedded AML 1 tissue, and each
slide was divided into four quadrants—upper left, lower
left, upper right, and lower right—to minimize the risk
of contamination of the derived samples. For all three
cellular components, DNA obtained from each quadrant
was analyzed for LOH and the 14-bp deletion. LOH
analysis was performed with Kg8, as well as with the
germline mutation (1-bp deletion in exon 33). Although
histologically all four quadrants looked similar, genetic
analysis clearly revealed the 14-bp deletion in blood-
vessel, smooth-muscle, and fat components in the upper-
left quadrant only, without evidence of LOH. The 14-
bp deletion, however, appeared to have occurred only
in a minor population of cells, as evidenced by the wild-
type–allele:mutant-allele intensity ratio in the whole-
tumor as well as in the laser-captured specimens (fig. 4).
Conversely, distinct LOH was detected with both mark-
ers in all three cellular components of the lower-right
quadrant only, without the 14-bp deletion. The upper-
right quadrant did not reveal either LOH or the 14-bp
deletion in any of the cells, and the lower-left quadrant
revealed LOH in muscle only, without evidence of either
LOH or the 14-bp deletion in either the blood-vessel or
the fat components (fig. 4). These results appear to rule
out the possibility of a second, cell-specific event occur-
ring in this AML; rather, these results demonstrate that
a second event occurred in all three components of this
AML. The two somatic mutations suggest either that
both somatic events arose independently in this tumor
or that this AML represents a mixture of at least two
distinct primary tumors.
LCMD was performed on tuber 5 from this patient,
and balloon cells within the tubers were isolated. As
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Figure 4 LCMD analysis of renal AML 1 (A1) from patient 9.
The three components of A1—blood vessels (V), smooth muscle (M),
and fat (F)—were microdissected from four quadrants of the slide:
upper left (UL), lower left (LL), upper right (UR), and lower right
(LR). DNA extracted from these cells was examined for two different
somatic mutations: the 14-bp deletion in exon 33 and LOH. LOH
analysis was performed with Kg8 and, in exon 33, the 1-bp deletion
representing the germline mutation (GLM). DNA samples from spleen
(SP) and AML 1 (A1), in its entirety, serve as controls. “NC” represents
DNA from a normal, unrelated person, as a control for the 1-bp
deletion. The 14-bp deletion is seen in all three cellular components
of the upper-left quadrant, whereas LOH is observed in all three cell
types of the lower-right quadrant. In the lower-left quadrant, only
muscle shows LOH, whereas the cell components in the upper-right
quadrant show neither the 14-bp deletion nor LOH.
Figure 5 LOH analysis of balloon cells microdissected from tu-
ber 5 of patient 9. Abnormal balloon cells (BC) microdissected from
cortical tuber 5, as well as neuron (N) and white matter (WM) taken
from the normal cortex, were analyzed for LOH. Neither Kg8 nor the
germline mutation (GLM) reveals LOH in the balloon cells. AML 1
(A1) and spleen (SP) serve as controls, and LOH is detected in AML
1, as expected. “NC” represents a normal, unrelated person.
controls, neurons and white matter were also dissected
from the histologically normal cortex of this patient.
These cells were subjected to LOH analysis with Kg8
and the 1-bp deletion in TSC2 exon 33 as markers. Bal-
loon cells did not reveal LOH for these markers when
compared with either normal spleen cells or the micro-
dissected neurons and white matter (fig. 5).
Clonality Analysis
The lack of somatic mutations in some of the TSC
lesions could also reflect a mixture of normal and ab-
normal cells in these lesions. We therefore performed
clonality analysis by PCR amplification of the highly
polymorphic HUMARA in female patients. Five of the
eight female patients were informative for this marker.
Two others (patients 1 and 5) were not informative, and
the DNA was insufficient for analysis of patient 4. Renal
AMLs from patients 2 and 7 were clearly clonal in ori-
gin, compared to those in the respective germline con-
trols (fig. 6). The three LAM samples from patient 8
were all polyclonal. Of the three analyzed AMLs from
patient 10, only one was clonal (fig. 6), although all three
tumors displayed LOH for TSC2. In patient 9, DNA
from several hamartomas was tested for clonality, along
with that from normal tissues such as spleen and muscle.
Two bands with closely matched intensities were evident
in the HpaII-digested normal spleen and muscle tissues
(fig. 6). The analyzed hamartoma tissues from this pa-
tient, however, revealed varied clonality. Of the two
AMLs, AML 1 was monoclonal in origin, with a CR
(see “Subjects and Methods”) of 3.50, whereas AML 2
was polyclonal. Of the five tubers analyzed, tuber 1 was
clonal, with a CR of 3.80, tubers 2–4 were polyclonal,
and tuber 5 was skewed toward one allele, with a CR
of 2.94. Similarly, of the two SEGAs, SEGA 1 revealed
a skewed pattern, with a CR of 2.73, and SEGA 2 was
polyclonal. The UF from this patient was clonal, with a
CR value of 3.88, and the gastric polyp was polyclonal.
The analyses performed on all of the hamartomas, as
well as the respective germline mutations, are summa-
rized in table 1.
Discussion
We have performed a comprehensive screen for inacti-
vating mutations in the coding exons of both TSC1 and
TSC2, on 24 lesions from 10 patients with TSC. Our
results clearly support the idea that complete inactiva-
tion of the TSC genes is characteristic of renal AMLs
but not of other TSC lesions, including cortical tubers.
LCMD performed on one of the AML samples from
patient 9 showed that blood-vessel, smooth-muscle, and
fat tissues all harbor the same second, somatic mutation
in at least one portion of the tumor, whereas results from
other regions of the tumor were inconclusive. Our data
differ from those of a previous report, which demon-
strated, also by microdissection, LOH in smooth muscle
and in fat but not in blood vessels, although the authors
of that study noted the absence of tuberin immuno-
staining in all three cell types (Henske et al. 1997).
Clearly, careful analysis of additional AMLs by LCMD
is necessary to confirm that these three cell types are
derived from a common precursor cell. We observed two
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Figure 6 Clonality analysis by HUMARA PCR. In polyclonal
tissues, undigested samples, denoted as “HpaII(),” and digested sam-
ples, denoted as “HpaII(),” produce two bands. In clonal tissues,
although undigested samples produce two bands, the digested samples
reveal a significant reduction in the intensity of one of the bands (in
an unmethylated allele). Compared to control blood DNA (B), renal
AMLs (A) from patients 2 and 7 (P2 and P7) show clear clonality.
Three lung LAMs (L1–L3) from patient 8 (P8) are polyclonal. In pa-
tient 10 (P10), AML 2 (A2) is clonal, whereas AML 1 and AML 3
are polyclonal. Multiple lesions of patient 9 (P9) show varied clon-
alities. Renal AML 1 (A1), cortical tuber 1 (T1), and a UF (UF) show
clear clonality. Cortical tuber 5 (T5) and SEGA 1 (S1) are skewed
toward the upper allele. Other hamartomas, including AML 2 (A2),
tubers 2–4 (T2–T4), and SEGA 2 (S2), appear to be polyclonal. DNA
from spleen (SP) and from muscle (M) of this patient serve as controls.
DNA from an unrelated male (MC) serves as a control, for complete
digestion of the samples by HpaII.
different somatic mutations—LOH and a 14-bp deletion
of TSC2 in AML 1—whose presence suggested either
that the two mutations arose successively (i.e., the 14-
bp deletion was followed by LOH) or that AML 1 is a
mixture of two different tumors with an identical X
chromosome–inactivation pattern. Nevertheless, it is
clear that the renal AMLs in TSC follow the classic
Knudson model, requiring a second somatic mutation
in the wild-type allele. None of the other tumors ana-
lyzed, except one SEGA (from patient 4), revealed the
loss of the second allele of either TSC1 or TSC2.
The inability to identify a second, somatic event in
either TSC1 or TSC2 in many tumor samples raises a
number of different possibilities. For instance, trans-
heterozygous mutations could occur, as shown in auto-
somal dominant polycystic kidney disease, with inac-
tivation of one allele at each of the PKD1 and PKD2
loci (Koptides et al. 2000; Watnick et al. 2000). We
screened all tumor samples for somatic events in both
TSC1 and TSC2 and found no evidence of a trans-
heterozygous event. However, concurrent mutations in
one or more other genes remain a possibility. Another
potential mechanism for inactivation of the wild-type
allele is somatic methylation, which is increasingly im-
plicated in the pathogenesis of human cancers (Merlo
et al. 1995). One study reports hypermethylation of the
von Hippel–Lindau gene in 33% of tumors that do not
display LOH (Prowse et al. 1997). We examined this
possibility and found no evidence of methylation within
TSC2 exon 1a near a defined promoter element. It is
generally believed that many of the lesions seen in TSC
are of mixed cell type, and a true tumor-cell population
could be low in abundance, resulting in a failure to
detect the somatic events by LOH analysis. Detailed
studies performed on LAM samples indicate that LAM
cells are nearly always tightly intermixed with other cell
types (Carsillo et al. 2000). To address this, we per-
formed clonality analysis, which revealed that some of
the lesions that showed absence of a somatic mutation
were indeed polyclonal. In particular, the three LAM
samples derived from patient 8 were polyclonal, sug-
gesting that the somatic event in these lesions could have
been masked by stromal contamination. Of the three
analyzed AMLs from patient 10, two were polyclonal
and one was clonal, although all three tumors showed
evidence of LOH. That nonclonal AMLs reveal LOH
again suggests that these could be mixtures of individual
tumors with similar LOH events. On the contrary, AML
1 from patient 9 was clonal, with the loss of both alleles
of TSC2, and AML 2 was polyclonal, with the somatic
event unidentified. Of the other lesions from patient 9,
tuber 1 and the UF were clearly clonal, whereas tuber
5 and one SEGA contained a relatively high propor-
tion of clonal cells, and the possibility of detecting the
somatic events would be predicted. Both SSCP and
DHPLC analyses of these tumors did not detect subtle
mutations, and Southern blot analysis and long-range
PCR failed to reveal other intragenic deletions. The lat-
ter two techniques may not be ideal if only minor por-
tions of the samples carry the mutations, but these as-
says should detect the mutations in lesions that have
clonal cells that constitute 50% of the population.
RT-PCR performed on the tubers showed equal ex-
pression of both alleles. In addition, the balloon cells
microdissected from one of the tubers also failed to
reveal loss of the other allele. Thus, although lack of
detection of a somatic mutation event could be due to
an admixture of normal cells in tumors that are poly-
clonal, this cannot provide an explanation in tumors
that are clonally derived.
Previous studies, as well as the present study, show
that a majority of AMLs seen in TSC are associated
with loss of the wild-type allele, primarily as LOH. It
has been suggested that tumorigenesis in UFs and brain
lesions probably does not require the extensive LOH
seen in AMLs and could be associated with subtle var-
iations in the TSC genes (Au et al. 1999). We have
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carefully searched for and found no evidence of subtle
variations of the TSC genes in many of the lesions,
particularly brain lesions. This suggests the possibility
that haplo-insufficiency of TSC1 and TSC2 genes may
be sufficient for TSC-lesion development in some cases.
There is increasing evidence that haplo-insufficiency for
other tumor-suppressor genes—such as NF1 (Ingram et
al. 2000; Cichowski and Jacks 2001), PTEN (Marsh et
al. 1998), and p53 (Venkatachalam et al. 1998)—may
be pathogenic. Retention of the wild-type allele has
also been demonstrated in tumors derived from murine
models heterozygous for p53, p27Kip1, and PTEN in-
activation (Di Cristofano et al. 1998; Fero et al. 1998;
Venkatachalam et al. 1998; Podsypanina et al. 1999).
Haplo-insufficiency of these tumor-suppressor genes
could be explained in a number of ways. Haploid levels
of tumor-suppressor proteins may be inadequate to reg-
ulate the activity of downstream target proteins that
might play a role in growth stimulation in some cell
types. Other possibilities include (a) the germline mu-
tation acting in a dominant-negative fashion to block
activity of the wild-type allele in tumors and (b) the
expression of the wild-type protein being “turned off”
or reduced as a result of epigenetic events or cooperating
mutations in genes other than those for TSC (Macleod
2000). It is therefore possible that a second, somatic
mutation may not be strictly necessary for all cell types
involved in TSC lesions. Immunohistochemistry studies
performed for tuberin and hamartin in brain lesions
yield variable findings—with moderate to no reactivity
for tuberin in SEGAs (Kerfoot et al. 1996; Arai et al.
1999; Plank et al. 1999) and with positive immuno-
reactivity for tuberin and hamartin in dysmorphic neu-
rons of cortical tubers (Johnson et al. 1999; Mizuguchi
et al. 2000), further supporting the idea that the TSC
proteins are not completely lost in these lesions. Further
detailed analysis of the fate of the wild-type allele in
human TSC lesions other than AMLs, as well as in
lesions that develop in mouse models of TSC, is essential
for exploration of whether (a) subtle, second-hit mu-
tations are occurring, (b) haplo-insufficiency alone is
sufficient, or (c) other genetic/epigenetic events are in-
volved in TSC-lesion development.
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